

THERAPEUTICS



WEEKLY SUPPLY



Since November, the state has received a weekly supply of bamlanivimab and casirivimab and imdevimab (Regeneron) from the Department of Health and Human Services, shipped directly to health care centers across the state. These therapies are neutralizing monoclonal antibodies targeting the SARS-CoV-2 spike protein.

1 HOUR ADMINISTERING

Each investigational drug is available through an Emergency Use Authorization (EUA) and is administered through an IV for over one hour, followed by one hour of post-infusion monitoring.



1 hr. administering



1 hr. monitoring

PHASE 2 TRIAL

Both studies limited enrollment to nonhospitalized persons with mild to moderate COVID-19, with increased risk for developing severe COVID-19 disease. These investigational drugs are now available at a number of infusion sites across the state.

75%




The percent bamlanivimab was found to reduce hospitalizations

50%-59%



The percent the combination of casirivimab and imdevimab reduced medically attended visits

EQUAL ACCESS



At this time, there is ample supply of the drugs available. However, if the demand for treatment exceeds the limited number of infusion center appointments, the state will use a lottery system to assign therapy to ensure equal access to everyone in the state.

COVID-19 TREATMENTS



Information about monoclonal antibody therapy and infusion centers, including information on which patients these treatments are appropriate for and how providers can prescribe this treatment to their patients, can be found at [COVID-19 treatments](#)

ELIGIBILITY



Once a provider determines that a patient meets eligibility criteria, they will be directed to a website to register their patient. If the patient is selected to receive treatment, the infusion center will contact the patient directly for scheduling.

MORE INFORMATION



- » [Casirivimab and imdevimab EUA](#)
- » [Bamlanivimab EUA](#)
- » [Medication Random Allocation Tool](#)
- » [Map of Current Infusion Sites](#)